Auditory Slow Wave Enhancement After Concussion

March 29, 2023 updated by: University Children's Hospital, Zurich

The Effect of Sleep and Slow Wave Enhancement on Recovery From a Concussion in Children and Adolescents: A Longitudinal, Randomized, Double-Blind, and Sham-Controlled Study

The prevalence of a traumatic brain injury (TBI) in children and adolescents is around 30% with 70-90% being classified as mild (concussion). Because the brain of a child is still developing, a TBI can have devastating effects and possibly creates lifetime challenges. Sleep seems to play an important role in the post-concussion recovery process. Auditory stimulation during sleep has been shown to reliably boost slow waves, a solid marker for the depth of sleep, and can thus be used to deepen sleep. This study aims to investigate the effects of sleep enhancement via auditory stimulation on recovery after a concussion in children and adolescents in their home. Therefore, half of the patients receive one week of auditory stimulation during deep sleep at their home using a mobile device. The other half follows the same study protocol, but no tones are administered (sham). Cognitive tests as well as symptom questionnaires are used to assess the recovery process. It is hypothesized that the patients in the intervention group will recover better than the ones who haven't received the intervention. Additionally, a group of children and adolescents who never sustained a concussion is included as a control.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

In total, 120 participants are planned: 60 patients (30 intervention, 30 sham) and 60 controls (30 intervention, 30 sham). This was estimated from a power analysis and based on previous results. Patients are recruited from the University Children's Hospital Zurich.

At first, the participants will complete a baseline assessment of neuropsychological measures (cognitive tests and questionnaires). After completion of the baseline assessment, the participants receive deep sleep enhancement with auditory stimulation for seven nights, but half of them will only receive sham stimulation (device application, but no stimulation). Additionally, they wear an actigraph throughout the whole week. Afterwards, they fill in again some questionnaires (intermediate assessment). One month after study inclusion, the first follow-up will take place where neuropsychological and (optionally) neurological measures will be collected. The second follow-up takes place six months after study inclusion and involves again filling in questionnaires about post-concussive symptoms.

The study will be monitored regularly in terms of data validation and source data verification. Adverse events and device deficiencies are carefully documented and reported according to the guidelines of swissmedic and the responsible ethics committee.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Zurich, Switzerland, 8032
        • Recruiting
        • University Children's Hospital Zurich
        • Contact:
          • Reto Huber

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed Consent as documented by signature
  • Age between 6 and 18 years
  • Good knowledge of German of the patient and at least one legal representative
  • Patients: Presentation to the Emergency of the University Children's Hospital Zurich because of a concussion (diagnosed by medical doctor)

Exclusion Criteria:

  • Preterm birth (< 37 gestational weeks)
  • Diagnosed hearing disorder
  • Psychiatric, syndromal, or neurological pre-existing condition (except for previous concussion)
  • Skin disorder/skin problem in the face/ear area that requires Treatment
  • Usage of neuroactive substances
  • Patients: Concomitant injury that requires intense pain medication or a prolonged hospital stay, or that causes limited use of the dominant Hand
  • Patients: Previous moderate-severe TBI
  • Controls: Injury of the dominant hand, on head, arm, or leg
  • Controls: Previous TBI (of any severity)

Additional inclusion criteria for the optional MRI measurement for both groups:

  • Age at least 8 years
  • Fulfilment of all MRI safety criteria
  • The participant and the legal representative would want to know about incidental findings.
  • Girls: No pregnancy or breast feeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Participants in this group will receive all-night auditory stimulation during sleep over one week using a portable, in-home device (MHSL-SleepBand).
The device records biosignals and precisely plays tones to enhance sleep slow waves.
Sham Comparator: Control group
Participants in this group will receive sham-stimulation, i.e. the device will be applied (biosignals will be recorded), but no tones will be played.
The device records biosignals and precisely plays tones to enhance sleep slow waves.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive Performance - attention
Time Frame: Measured one month after study inclusion.
Assessed by standardized test (normative values).
Measured one month after study inclusion.
Cognitive Performance - processing speed
Time Frame: Measured one month after study inclusion.
Assessed by standardized test (normative values).
Measured one month after study inclusion.
Cognitive Performance - executive function
Time Frame: Measured one month after study inclusion.
Assessed by standardized test (normative values).
Measured one month after study inclusion.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective recovery
Time Frame: Measured at baseline, one week later (intermediate assessment), one month later (follow-up 1) and six months later (follow-up 2).
Assessed by standardized symptom questionnaires.
Measured at baseline, one week later (intermediate assessment), one month later (follow-up 1) and six months later (follow-up 2).
Algorithm performance
Time Frame: Recorded during seven nights of stimulation or sham (intervention week).
The algorithm flags which are produced by the mobile device used for the auditory stimulation (i.e. sleep detection flags, stimulation flags). They are used to investigate the algorithm performance for each subject.
Recorded during seven nights of stimulation or sham (intervention week).
Neurological outcome
Time Frame: One month after study inclusion (follow-up 1).
Measured using Magnetic Resonance Imaging (standard structural and hemodynamic imaging, DTI, and susceptibility weighting) to investigate the neurological outcome.
One month after study inclusion (follow-up 1).
Injury characteristics
Time Frame: baseline, pre-intervention
Only for patients: Injury characteristics collected from the Hospital Information System that might influence baseline and follow-up measures and their change over time.
baseline, pre-intervention
Other possible moderators of the Intervention
Time Frame: Collected at the baseline assessment.
For example age and socio-economic status.
Collected at the baseline assessment.
EEG power
Time Frame: Recorded during the intervention week.
Power in frequency bands (delta, theta, alpha, beta, gramma).
Recorded during the intervention week.
Sleep stages
Time Frame: Recorded during the intervention week.
EEG, EOG and EMG used for sleep scoring (sleep stages).
Recorded during the intervention week.
Sleep EEG characteristics
Time Frame: Recorded during the intervention week.
Characteristics of sleep EEG Features (slow waves, spindles).
Recorded during the intervention week.
Subjective sleep
Time Frame: Collected throughout the whole study participation, in total 6 months (baseline, one week later (intermediate assessment), one month later (follow-up 1) and six months later (follow-up 2)).
Assessed by standardized questionnaire
Collected throughout the whole study participation, in total 6 months (baseline, one week later (intermediate assessment), one month later (follow-up 1) and six months later (follow-up 2)).
Actigraphy
Time Frame: Recorded during the intervention week.
Measured by GENEActiv (activity bouts).
Recorded during the intervention week.
Objective and subjective sleep measures
Time Frame: Recorded at all study visits over a period of six months (baseline assessment, intervention week, follow-up 1 and follow-up 2)..
Sleep measured by EEG and actigraphy (objective) as well as questionnaires (subjective)
Recorded at all study visits over a period of six months (baseline assessment, intervention week, follow-up 1 and follow-up 2)..

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intervention tolerability
Time Frame: After the intervention week (one week after study inclusion).
Measured using an intervention evaluation questionnaire (self-designed).
After the intervention week (one week after study inclusion).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Reto Huber, Prof., University Children's Hospital, Zurich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2021

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

February 16, 2021

First Submitted That Met QC Criteria

February 22, 2021

First Posted (Actual)

February 25, 2021

Study Record Updates

Last Update Posted (Actual)

March 30, 2023

Last Update Submitted That Met QC Criteria

March 29, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Concussion Post Syndrome

Clinical Trials on Auditory Stimulation

3
Subscribe